PRMT5-IN-33 

PRMT5-IN-33 (compound A8) is a selective, SAM-competitve PRMT5 inhibitors with IC₅₀ of 10.9 nM. PRMT5-IN-33 induces apoptosis and inhibits proliferation of cells Z-138 and MOLM-13. PRMT5-IN-33 exhibits an antitumor activity^[1].

PRMT5-IN-33 inhibits proliferation of cells Z-138 and MOLM-13, with IC₅₀s of 123.2 nM and 248.6 nM, respectively^[1].
PRMT5-IN-33 decreases levels of arginine symmetrical dimethylation (sDMA) in a dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PRMT5-IN-33 (60-120 mg/kg, i.g.,twice a day for 13 days) inhibits the MOLM-13 xenograft tumor growth in a dose-dependent manner in BALB/c mice without a body weight loss^[1].
PRMT5-IN-33 (p.o., 10 mg/kg, single dosage) reveals a pharmacokinetic profils in ICR mice^[1]:
.
Pharmacokinetic Analysis of PRMT5-IN-33 in ICR mice^[1]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

554.46

C₂₅H₂₄BrN₅O₃S

BrC1=CC2=CC=C(C=C2N=C1N)CC[C@@H]3[C@H]([C@H]([C@@H](C3)NC4=C(C=NC=N4)C(C5=CSC=C5)=O)O)O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Chen Y, et al., Structure-based discovery of a new series of nucleoside-derived ring-opening PRMT5 inhibitors. Eur J Med Chem. 2024 Jan 28;267:116171.  [Content Brief]